New Delhi: The UK’s anti-trust regulator stated on Monday that listening to system maker Cochlear and Copenhagen-based Demant had denied that the Australian agency’s buy of Demant’s listening to implants enterprise would result in any competitors issues.

The Competitors and Markets Authority (CMA) stated in an announcement that each Demant and Cochlear contested the regulator’s Section 1 findings that different listening to options aren’t good options for bone conduction implants.

The CMA has set a June 5 deadline for its in-depth section 2 probe into Cochlear’s buy of Demant’s Oticon Medical enterprise.